CD274 and neoplasm: The 12 months OS was superior with pembrolizumab vs. chemotherapy in elderly patients with PD-L1 Tumor Proportion Score (TPS) ≥ 1% (HR: 0.76 (95% CI: 0.56–1.02)) and with PD-L1 TPS ≥ 50% (HR: 0.40 (95% CI, 0.25–0.64)).